Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma

20 Sep 2018

• By Joseph Haas, Jo Shorthouse, and Kevin Grogan

Takeda and Molecular Templates will work to develop targeted engineered toxin bodies for multiple myeloma. Celgene decides against optioning OncoMed’s navicixizumab for ovarian cancer, while CRISPR and ViaCyte team up on type 1 diabetes.

Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma

More from Deals

More from Business